Owlstone Medical’s ReCIVA Named Invention of the Year in Top 50 Digital Health Awards

« Back to Industry News

07/12/2016

Cambridge, UK, 6 December 2016: Owlstone Medical, a diagnostics company developing a breathalyzer for disease, announced today that its ReCIVA breath sampling and analysis technology has been named Invention of the Year in the 2017 Top 50 in Digital Health Awards. 

Each year ahead of the JP Morgan Health Conference in San Francisco, fifty of the leading entrepreneurs, investors, technologists, reporters, and providers dedicated to bringing technological advancements to healthcare are recognized at the Top 50 in Digital Health Dinner hosted by Rock Health, Fenwick & West, Goldman Sachs, and Square 1 Bank. Within the Top 50, a number of individuals and organizations are awarded through public nominations and votes from the digital health community for making exceptional progress in driving resources, attention, and innovation toward a massively better healthcare system. 

Owlstone Medical uses the Respiration Collector for In Vitro Analysis (ReCIVA), in combination with the Field Asymmetric Ion Mobility Spectrometer (FAIMS) sensor platform, to accurately and selectively detect targeted biomarkers of disease in breath (and other bodily fluids). 

Billy Boyle, co-founder and CEO at Owlstone Medical, said: “We are delighted that ReCIVA has been named Invention in the 2017 Top 50 Digital Health Awards. Our vision is to save 100,000 lives and $1.5B in health care costs by 2020 with a breath sampling and analysis technology that can diagnose cancer and other diseases earlier than existing tests. This allows for more effective treatment and ultimately, better patient survival rates and reduced treatment costs.” 


Click here to view the related article.

« Back to Industry News